Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000886163-20-000045
Filing Date
2020-04-24
Accepted
2020-04-24 16:06:05
Documents
10
Period of Report
2020-04-24
Effectiveness Date
2020-04-24

Document Format Files

Seq Description Document Type Size
1 DEF 14A lgnd-2020annualmeetingproxy.htm DEF 14A 1132750
2 a2020annualmeetingnotice1o.jpg GRAPHIC 333880
3 a2020annualmeetingnotice2o.jpg GRAPHIC 257362
4 image1a011.gif GRAPHIC 565
5 image21.gif GRAPHIC 1174
6 image31.gif GRAPHIC 612
7 image41.gif GRAPHIC 431
8 ligandlogo417191.jpg GRAPHIC 12141
9 ligandlogo41719a011.jpg GRAPHIC 12141
10 stockgraph_2251.jpg GRAPHIC 199676
  Complete submission text file 0000886163-20-000045.txt   2239429
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33093 | Film No.: 20814998
SIC: 2834 Pharmaceutical Preparations